The Effect of an Interactive Web-based Program in the Management of Multiple Sclerosis
The Evaluation of the Effect of an Interactive Web-based Program That Supports Nurse-led Self-regulation in the Management of Multiple Sclerosis
1 other identifier
interventional
76
1 country
1
Brief Summary
This study aimed to investigate the effect of an interactive web-based program that supports nurse-led self-regulation in the management of Multiple Sclerosis (MS) on the self-management, fatigue and anxiety levels of patients with Multiple Sclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable multiple-sclerosis
Started Jun 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2022
CompletedFirst Posted
Study publicly available on registry
May 26, 2022
CompletedStudy Start
First participant enrolled
June 13, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2023
CompletedSeptember 13, 2023
September 1, 2023
3 months
May 20, 2022
September 11, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in self-management
The Multiple Sclerosis Self-Management Scale (MSSM) will be used to assess self-management knowledge and behavior of individuals with MS comprehensively and psychometrically. The MSSM consists of 24 Likert-type items with re-sponses as follows: disagree completely (1 point), somewhat disagree (2 points), neither agree nor dis-agree (3 points), somewhat agree (4 points), and agreecompletely (5 points). The MSSM includes 5 subscales: healthcare providerrelationship/communication, treatment adherence/barriers, social/family support, MS knowledge and information, and health maintenance behavior. Total score ranges between 0 and 100, and a higherscore indicates a higher degree of self-management.
Baseline and 8 weeks after patient inclusion
Secondary Outcomes (4)
Fatigue Severity Scale
Baseline and 8 weeks after patient inclusion
State-Trait Anxiety Inventory (STAI)
Baseline and 8 weeks after patient inclusion
System Usability Scale
8 weeks after patient inclusion
Program Usage Level Tracking Form
8 weeks after patient inclusion
Study Arms (2)
experimental
EXPERIMENTALExperimental: Intervention group "Yönetebilirim" Before the initiation of the program, patients who visit the outpatient clinic will be evaluated according to the inclusion-exclusion criteria, their consent will be obtained, and pre-tests will be administered. Then, randomization will be performed and participants will be assigned to the experimental and control groups. Participants in the experimental group will be registered on the web-based program. The individuals in the experimental group will use "Yönetebilirim" for 8 weeks as of the time the program is put into use. "Yönetebilirim" consists of modules and consultancy services. Participants will be able to watch informative videos as much as they want for 8 weeks and receive consultancy service if they wish.
Control
NO INTERVENTIONThe control group will receive standard care without any intervention. The group will not receive any other intervention.
Interventions
"Yönetebilirim" is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses.
Eligibility Criteria
You may qualify if:
- To be diagnosed with Multiple Sclerosis,
- Expanded Disability Status Scale (EDSS) score below 5,
- Be in the 7-12 age range18-65,
- Having the ability to read and write,
- To be able to communicate in Turkish
- Being able to access and use the Internet (computer, tablet, mobile phone)
You may not qualify if:
- To have received steroid treatment for an attack in the last month
- Having a psychiatric diagnosis (schizophrenia, bipolar affective disorder etc.)
- Having advanced cognitive problems
- Being visually and hearing impaired.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Selcuk University
Selçuklu, Konya, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Selda Arslan, Phd
Necmettin Erbakan University Faculty of Nursing
- PRINCIPAL INVESTIGATOR
Ayyüce Tuba Koçak, MSC
Selcuk University Faculty of Nursing
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Research assistant
Study Record Dates
First Submitted
May 20, 2022
First Posted
May 26, 2022
Study Start
June 13, 2022
Primary Completion
September 1, 2022
Study Completion
June 1, 2023
Last Updated
September 13, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- 3 mounts later